$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2024 Q2 Form 10-Q Financial Statement

#000141057824000820 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.060M $1.513M
YoY Change -22.41% -32.06%
% of Gross Profit
Research & Development $922.0K $961.0K
YoY Change -67.0% -67.13%
% of Gross Profit
Depreciation & Amortization $64.00K $64.00K
YoY Change -4.48% -4.48%
% of Gross Profit
Operating Expenses $922.0K $961.0K
YoY Change -67.0% -67.13%
Operating Profit -$2.982M -$2.474M
YoY Change -45.27% -51.97%
Interest Expense $411.0K -$940.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $30.00K $13.00K
YoY Change -75.0% -85.87%
Pretax Income -$2.541M -$3.401M
YoY Change -52.32% -32.77%
Income Tax
% Of Pretax Income
Net Earnings -$2.541M -$3.401M
YoY Change -52.32% -32.77%
Net Earnings / Revenue
Basic Earnings Per Share -$0.04 -$0.05
Diluted Earnings Per Share -$0.04 -$0.05
COMMON SHARES
Basic Shares Outstanding 70.08M 68.34M
Diluted Shares Outstanding 71.22M 64.74M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.469M $779.0K
YoY Change 363.77% -65.02%
Cash & Equivalents $3.469M $779.0K
Short-Term Investments
Other Short-Term Assets $314.0K $454.0K
YoY Change -15.59% -31.0%
Inventory
Prepaid Expenses
Receivables $33.00K $26.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $3.816M $1.259M
YoY Change 214.59% -57.02%
LONG-TERM ASSETS
Property, Plant & Equipment $558.0K $622.0K
YoY Change -30.16% -28.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.867M $2.089M
YoY Change -58.82% -57.74%
Total Long-Term Assets $1.867M $2.089M
YoY Change -58.82% -57.74%
TOTAL ASSETS
Total Short-Term Assets $3.816M $1.259M
Total Long-Term Assets $1.867M $2.089M
Total Assets $5.683M $3.348M
YoY Change -1.11% -57.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.340M $4.690M
YoY Change 2.89% -39.89%
Accrued Expenses $718.0K $636.0K
YoY Change 697.78% 271.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.691M $6.831M
YoY Change 0.0% -34.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.519M $2.067M
YoY Change -21.62% -9.74%
Total Long-Term Liabilities $1.519M $2.067M
YoY Change -21.62% -9.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.691M $6.831M
Total Long-Term Liabilities $1.519M $2.067M
Total Liabilities $9.210M $8.898M
YoY Change -4.35% -30.0%
SHAREHOLDERS EQUITY
Retained Earnings -$221.0M -$218.0M
YoY Change 6.25% 7.45%
Common Stock $217.5M $213.0M
YoY Change 6.41% 7.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.527M -$5.550M
YoY Change
Total Liabilities & Shareholders Equity $5.683M $3.348M
YoY Change -1.11% -57.47%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$2.541M -$3.401M
YoY Change -52.32% -32.77%
Depreciation, Depletion And Amortization $64.00K $64.00K
YoY Change -4.48% -4.48%
Cash From Operating Activities -$1.683M -$3.063M
YoY Change -75.17% -23.16%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.370M 2.539M
YoY Change -17.53% -21.39%
NET CHANGE
Cash From Operating Activities -1.683M -3.063M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 4.370M 2.539M
Net Change In Cash 2.687M -524.0K
YoY Change -282.17% -141.95%
FREE CASH FLOW
Cash From Operating Activities -$1.683M -$3.063M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001137883
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68447193
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60489208
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-36641
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
NY
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
CY2024Q1 dei City Area Code
CityAreaCode
201
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
488-0460
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
CY2024Q1 dei Trading Symbol
TradingSymbol
BCLI
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70080523
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
779000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1300000
CY2024Q1 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
26000
CY2023Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
51000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
454000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
548000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
1259000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1899000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
20000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
22000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
182000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
185000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1265000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1416000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
622000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
686000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2089000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2309000
CY2024Q1 us-gaap Assets
Assets
3348000
CY2023Q4 us-gaap Assets
Assets
4208000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4690000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4954000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
636000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1240000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
588000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
603000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
917000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1003000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6831000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7800000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
533000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
672000
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
1534000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1266000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
594000
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2067000
CY2024Q1 us-gaap Liabilities
Liabilities
8898000
CY2023Q4 us-gaap Liabilities
Liabilities
9066000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
13000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68447193
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60489208
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
212967000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
210258000
CY2024Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218414000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215013000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-5550000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4858000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3348000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4208000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
961000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2924000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1513000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2227000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2474000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5151000
CY2024Q1 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-13000
CY2023Q1 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-92000
CY2024Q1 bcli Fair Value Adjustments Of Warrants And Stock Issuance Costs
FairValueAdjustmentsOfWarrantsAndStockIssuanceCosts
940000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3401000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5059000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64738544
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64738544
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36735435
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36735435
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3015000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4000
CY2023Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
3230000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5059000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4840000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4858000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
170000
CY2024Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
2539000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3401000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-5550000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3401000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-5059000
CY2024Q1 us-gaap Depreciation
Depreciation
64000
CY2023Q1 us-gaap Depreciation
Depreciation
67000
CY2024Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
170000
CY2023Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
4000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-79000
CY2024Q1 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-121000
CY2023Q1 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
579000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-264000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1578000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
940000
CY2024Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-690000
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
82000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3063000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3986000
CY2023Q1 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-2005000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2005000
CY2024Q1 bcli Proceeds From At Market
ProceedsFromAtMarket
2539000
CY2023Q1 bcli Proceeds From At Market
ProceedsFromAtMarket
3230000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2539000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3230000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-524000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1249000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1485000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
772000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
961000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2021000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218000000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1265000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1416000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1121000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1275000
CY2024Q1 us-gaap Lease Cost
LeaseCost
164000
CY2023 us-gaap Lease Cost
LeaseCost
1467000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">D.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Use of estimates</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 82.8pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p>
CY2024Q1 bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
CY2024Q1 bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
166000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
386000
CY2024Q1 bcli Operating Lease Expense Income
OperatingLeaseExpenseIncome
165000
CY2023Q1 bcli Operating Lease Expense Income
OperatingLeaseExpenseIncome
40000
CY2024Q1 bcli Finance Lease Expenses Income
FinanceLeaseExpensesIncome
-1000
CY2023Q1 bcli Finance Lease Expenses Income
FinanceLeaseExpensesIncome
118000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M17D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0862
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
452000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
568000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
186000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1206000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
85000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1121000
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
174000000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
170000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4000
CY2024Q1 bcli Number Of Shareholders Filed Complaints
NumberOfShareholdersFiledComplaints
4
CY2024Q1 bcli Number Of Shareholders Filed Complaints
NumberOfShareholdersFiledComplaints
4
CY2024Q1 bcli Number Of Shareholders Filed Complaints
NumberOfShareholdersFiledComplaints
4

Files In Submission

Name View Source Status
0001410578-24-000820-index-headers.html Edgar Link pending
0001410578-24-000820-index.html Edgar Link pending
0001410578-24-000820.txt Edgar Link pending
0001410578-24-000820-xbrl.zip Edgar Link pending
bcli-20240331.xsd Edgar Link pending
bcli-20240331x10q.htm Edgar Link pending
bcli-20240331xex31d1.htm Edgar Link pending
bcli-20240331x10q_htm.xml Edgar Link completed
bcli-20240331xex31d2.htm Edgar Link pending
bcli-20240331xex32d1.htm Edgar Link pending
bcli-20240331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bcli-20240331_def.xml Edgar Link unprocessable
bcli-20240331_pre.xml Edgar Link unprocessable
bcli-20240331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcli-20240331_cal.xml Edgar Link unprocessable